XCath Robotics’ Iris System Accepted into FDA’s Total Product Life Cycle Advisory Program (TAP) for Remote Robotic-Assisted Mechanical Thrombectomy in Acute Isc…

The U.S. Food and Drug Administration (FDA) has accepted XCath’s Iris Surgical Robotic System into its Total Product Life ...
MarketScreener

AbbVie's Telisotuzumab Adizutecan Receives Two Breakthrough Therapy Designations from the U.S. FDA for CRC and NSCLC

NORTH CHICAGO - AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration ( FDA) has granted two Breakthrough Therapy Designations (BTDs) for telisotuzumab adizutecan (Temab-A; ABBV-400 ...
MarketScreener

RBC Raises Price Target on Revolution Medicines to $259 From $251, Keeps Outperform Rating

Revolution Medicines has an average rating of buy and mean price target of $259.19, according to analysts polled by FactSet.